Picture of Quest PharmaTech logo

QPT Quest PharmaTech Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapContrarian

Momentum

Relative Strength (%)
1m-2.44%
3m-3.12%
6m-4.44%
1yr-68.53%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-64.29%
50d MA-1.96%
200d MA-54.34%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-4.59%
Return on Equity53.01%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Jan 202531st Jan 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Quest PharmaTech EPS forecast chart

Profile Summary

Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. It also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.

Directors

Last Annual
January 31st, 2024
Last Interim
April 30th, 2024
Incorporated
December 16th, 1996
Public Since
July 23rd, 1997
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconTSX Venture Exchange
Shares in Issue
169,129,247

QPT Share Price Performance

Upcoming Events for QPT

Q2 2025 Quest Pharmatech Inc Earnings Release

Quest Pharmatech Inc Annual Shareholders Meeting

Q3 2025 Quest Pharmatech Inc Earnings Release

Similar to QPT

Picture of Covalon Technologies logo

Covalon Technologies

ca flag iconTSX Venture Exchange

Picture of Hemostemix logo

Hemostemix

ca flag iconTSX Venture Exchange

Picture of Innovotech logo

Innovotech

ca flag iconTSX Venture Exchange

Picture of Kane Biotech logo

Kane Biotech

ca flag iconTSX Venture Exchange

Picture of KDA logo

KDA

ca flag iconTSX Venture Exchange

FAQ